News

ALS drug fails large clinical trial and may be withdrawn from market

todayMarch 8, 2024 14

Background
share close
Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show significant benefit in a large clinical trial and may be withdrawn from the market.

​ Amylyx Pharmaceuticals announced Friday that its drug for amyotrophic lateral sclerosis, or ALS, called Relyvrio, did not show significant benefit in a large clinical trial and may be withdrawn from the market. Read More Breaking News, Latest News and Videos | CNN 

Written by:

Rate it